Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence WorldwideJyh Yung Hor, Kazuo Fujihara, Nasrin Asgari et al.|Frontiers in Neurology|2020Cited by 399
Update on biomarkers in neuromyelitis opticaEsther Melamed, Danielle van Pelt, Michael Levy et al.|Neurology Neuroimmunology & Neuroinflammation|2015Cited by 119
Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStarTakashi Yamamura, Benjamin Greenberg, Brian G. Weinshenker et al.|Multiple Sclerosis and Related Disorders|2022Cited by 60
Restoring immune tolerance in neuromyelitis opticaAmit Bar‐Or, Kevin C. O’Connor, Jacinta M. Behne et al.|Neurology Neuroimmunology & Neuroinflammation|2016Cited by 57
Challenges and opportunities in designing clinical trials for neuromyelitis opticaBrian G. Weinshenker, Michael R. Yeaman, Gerard Barron et al.|Neurology|2015Cited by 46